Nature Metabolism: Carriers of Rare GLP1R Variants Lost Less Weight on Semaglutide but Responded Almost Normally to Tirzepatide
Using exome sequencing and health records from 13 North American health systems in the Helix Research Network, researchers studied 13,725 adults who started semaglutide or tirzepatide. Among semaglutide users, 17 carriers of rare GLP1R variants lost 2.4% of body weight vs. 8.8% in matched non-carriers, while 19 carriers on tirzepatide lost 13.3% vs. 15.2%, a difference that was not statistically significant; carriers of rare GIPR variants had near-normal responses. Follow-up was capped at 12 months, and the carrier groups were small.